Results 141 to 150 of about 2,595 (198)

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study. [PDF]

Cureus
Mihalache A, Volfson E, Huang R, Zuo K, Persitz J.   +4 more
europepmc   +1 more source

Mapping Lysosomal Storage Disorders with Neurological Features by Cellular Pathways: Towards Precision Medicine. [PDF]

Curr Issues Mol Biol
Makridou A, Sintou E, Chatzianagnosti S, Gargani S, Manthou ME, Dermitzakis I, Theotokis P.   +6 more
europepmc   +1 more source

MUSCULOSKELETAL ALTERATIONS OF ORTHOPEDIC INTEREST IN MUCOPOLYSACCHARIDOSES. [PDF]

Acta Ortop Bras
Matos MA, Lopes PS.
europepmc   +1 more source

RNA-based therapeutic interventions for the management of Anderson-Fabry disease. [PDF]

Mol Ther Nucleic Acids
Cagnin S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Identification of iduronate-2-sulfatase in mouse pancreatic islets

American Journal of Physiology-Endocrinology and Metabolism, 2004
The lysosomal enzyme iduronate-2-sulfatase (IDS) is expressed in pancreatic islets and is responsible for degradation of proteoglycans, such as perlecan and dermatan sulfate. To determine the role of IDS in islets, expression and regulation of the gene and localization of the enzyme were investigated in mouse pancreatic islets and clonal cells. The Ids
I, Coronado-Pons, A, Novials, S, Casas, A, Clark, R, Gomis   +4 more
openaire   +2 more sources

“Supercharged Cells” for Delivery of Recombinant Human Iduronate-2-Sulfatase

Molecular Genetics and Metabolism, 2000
Expression of iduronate-2-sulfatase (IDS) from three different promoters in four retroviral vectors was studied in peripheral blood lymphocytes from patients with Hunter syndrome (PBL(MPS)), i.e., the LTR in vectors L2SN and L2, avian beta-actin promoter in LB2, and the CMV early promoter in LNC2.
D, Pan, J J, Jonsson, S E, Braun, R S, McIvor, C B, Whitley   +4 more
openaire   +2 more sources

Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the Mouse

Drug Metabolism and Disposition, 2012
Mucopolysaccharidosis (MPS) type II (Hunter's syndrome) is caused by mutations in the iduronate 2-sulfatase (IDS) fusion protein. MPS-II affects the brain, and enzyme replacement therapy is not effective in the brain, because the enzyme does not cross the blood-brain barrier.
Qing-Hui, Zhou, Ruben J, Boado, Jeff Zhiqiang, Lu, Eric Ka-Wai, Hui, William M, Pardridge   +4 more
openaire   +2 more sources